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Abstract
Purpose: To establish a consensus in relation to case selection, conduct of therapy, and outcomes that are
associated with focal therapy for men with localized prostate cancer.
Material and Methods: Urologic surgeons, radiation oncologists, radiologists, and histopathologists from North
America and Europe participated in a consensus workshop on focal therapy for prostate cancer. The consensus
process was face to face within a structured meeting, in which pertinent clinical issues were raised, discussed,
and agreement sought. Where no agreement was possible, this was acknowledged, and the nature of the
disagreement noted.
Results: Candidates for focal treatment should have unilateral low- to intermediate-risk disease with clinical
stage cT2a. Prostate size and both tumor volume and tumor topography are important case selection criteria
that depend on the ablative technology used. Currently, the best method to ascertain the key characteristics for
men who are considering focal therapy is exposure to transperineal template mapping biopsies. MRI of the
prostate using novel techniques such as dynamic contrast enhancement and diffusion weighed imaging are
increasingly being used to diagnose and stage primary prostate cancer with excellent results. For general use,
however, these new techniques require validation in prospective clinical trials. Until such are performed, MRI
will, in most centers, continue to be an investigative tool in assessing eligibility of patients for focal therapy.
Conclusions: Consensus was derived for most of the key aspects of case selection, conduct of treatment, and
outcome measures for men who are undergoing focal therapy for localized prostate cancer. The level of
agreement achieved will pave the way for future collaborative trials.
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Introduction
During the past two decades, there has been a trendtoward earlier diagnosis of prostate cancer that stems
from greater public and professional awareness, leading to the
adoption of both formal and informal screening strategies.1 The
effect of this has been to identify men with smaller tumors at an
earlier stage that occupy only 5% to 10% of the prostate volume,
with a greater propensity for unifocal or unilateral disease.2–4
This observation has led several groups to explore whether the
prevailing strategy that has been adopted for the surgical
management of all other solid organ cancers could be applied to
the prostate. The strategy is one of organ preservation.
Urologists will recall the rather controversial minirevolu-
tion that partial nephrectomy induced. It did not take long
to replace radical nephrectomy as the treatment of choice for
a large number of patients with small tumors even in the
presence of a normal contralateral kidney. The same type of
revolution appears to be happening in prostate cancer treat-
ment. In 2007, three groups proposed that nondiseased
prostate tissue be left untreated in both the hope and expec-
tation that, as a result, genitourinary function might be pre-
served and the tumor treated adequately.5–7
Since these initial position articles. some investigators and
several clinicians have started to treat patients in a way that
preserves prostate tissue. This type of treatment has become
known as focal therapy. As a result, a number of approaches
have emerged, with each incorporating a diverse spectrum of
case selection algorithms, varying definitions of what is meant
by focal therapy, a number of energy sources, and a divergent
view of what is deemed a successful outcome.4,8
To identify areas in which agreement could be derived, a
1-day consensus meeting was organized. This article sum-
marizes the conduct and output of that meeting.
Materials and Methods
The consensus meeting was held on June 13, 2009, at the
end of the 2nd International Workshop on Focal Therapy and
Imaging in Prostate and Kidney Cancer (Amsterdam, The
Netherlands: www.focaltherapy.org). The contributors com-
prised a multidisciplinary and international panel of experts
and were selected on the basis of their expertise in any one or
more of the topics on the agenda for discussion. There were
representation and endorsement from the European Society
for Therapeutic Radiology and Oncology (ESTRO), the Eu-
ropean Organization for Research and Treatment of Cancer
(EORTC-GU), the European Association of Urology (EAU)
guidelines committee on prostate cancer, the EAU Section
of Urological Technology (ESUT), the Society of Urologic
Oncology (SUO) and the Endourological Society. The attri-
butes and affiliations of the contributors are described in
Table 1.
The conduct of the meeting conformed to an informal
consensus process in that no formal scoring system was used
to measure the level of agreement that existed before or after
the meeting.9 The process, however, did conform to the three
generally accepted stages of a consensus process.10 Items for
discussion were preselected and discussed by individual
members before the meeting and allocated a specific time
during the meeting. During the meeting, a brief presentation
was made by an invited expert (scene setting). This was used
Table 1. Attributes and Affiliations of the Contributors
Name Specialty Affiliation Expertise Country
J. de la Rosette Urology Endourological Society Uro-oncology Netherlands
H. Ahmed Urology Uro-oncology United Kingdom
J. Barentsz Radiology GU imaging (MRI) Netherlands
T. Bjerklund Johansen Urology Uro-oncology Denmark
M. Brausi Urology EORTC-GU Uro-oncology Italy
M. Emberton Urology EAU-ESUT Uro-oncology United Kingdom
F. Frauscher Radiology EAU-ESUI GU imaging (ultrasound) Austria
D. Greene Urology Uro-oncology United Kingdom
M. Harisinghani Radiology GU imaging (MRI) United States
K.Haustermans Radiation
oncology
ESTRO External radiation and
brachytherapy
Belgium
A Heidenreich Urology EAU Guidelines Uro-oncology Germany
G. Kovacs Radiation
oncology
ESTRO Certified brachytherapy
expert
Germany
M. Mason Radiation
oncology
EAU guidelines Oncology United Kingdom
R Montironi Pathology EAU Uropathology Italy
V. Mouraviev Urology Uro-oncology United States
Th.M. de Reijke Urology EORTC-GU Uro-oncology The Netherlands
S. Taneja Urology SUO Uro-oncology United Kingdom
S. Thuroff Urology EAU-ESUT Uro-oncology Germany
B. Tombal Urology EORTC-GU Uro-oncology Belgium
J. Trachtenberg Urology Endourological Society Uro-oncology Canada
H. Wijkstra Urology EAU-ESUI Imaging (ultrasound) Netherlands
T.J. Polascik Urology Endourological Society Uro-oncology United States
GU¼genitourinary; MRI¼magnetic resonance imaging; EORTC-GU¼European Organization for Research and Treatment of Cancer-
Genitourinary; EAU-ESUT¼European Association of Urology-Section of Urological Technology; EAU-ESUI¼European Association of
Urology-Section of Urological Imaging; ESTRO¼European Society for Therapeutic Radiology and Oncology; SUO¼ Society of Urologic
Oncology.
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as the basis for moderated discussion (Level 1). After this
discussion, any individual or group having concerns was
identified by the moderator and resolution sought (Level 2).
Once this had been completed a call for consensus was made
(Level 3). This was achieved by a show of hands.
Contributors who were not invited to present a scene-setting
preamble were aware of the items for discussion before the
meeting and therefore also had the opportunity to prepare.
Items selected for discussion are shown in Table 2. All con-
tributors to the consensus process have seen and approved this
manuscript and, by agreeing to authorship, concur with the
contents of this article.
Results
Definition of focal therapy
The following definition was agreed: Focal therapy is a type
of treatment that aims to eradicate known cancer within the
prostate and at the same time preserve uninvolved prostatic
tissue with the aim of preserving genitourinary function.
The discussion was mostly concentrated on the issue of
‘‘measurable disease.’’ It was accepted that because a biopsy
result was negative in one sector of the prostate, this did not
necessarily imply that the sector was free of disease. The
definition tries to embrace this view by use of the word
‘‘known.’’
The concept of ‘‘clinically important cancer’’ was discussed
in contrast to the notion of any measurable cancer. What this
concept introduces is that some low-volume cancers that are
of low grade are unlikely to be of any clinical relevance to a
person over a 15- to 20-year period. If this notion of ‘‘indolent’’
disease is accepted, then some focal therapy protagonists have
argued that low-volume, low-grade cancer could quite safely
be left in the untreated part of the prostate with little clinical
consequence.3,11,12 While this was thought to be an important
research question for the future, it was agreed that on the basis
of current evidence and expert opinion, untreated tissue
should be free of measurable disease.
Patient selection for focal therapy
The primary objective of treatment should be eradication
of measurable disease. This objective has as its aim a reduc-
tion in the risk of a prostate-cancer–related detrimental effect
on quality of life (QoL) or death. In addition, while the intent
of treatment should be for a one-time therapy, patients need to
be aware of the possibility of further treatment in the future.
Consensus was reached in a number of areas in relation to
candidate selection for focal therapy. These are summarized
in Table 3. The greatest area of contention was that of Gleason
grade. A number of panel members were of the opinion that
focal therapy should be regarded as an alternative to active
surveillance—men who were deemed to have low-risk, low-
volume disease that was normally suited for active surveil-
lance could have access to a treatment that provided a form
of therapy for their ‘‘cancer’’ with the greatest chance for
preservation of genitourinary functions. This is based on the
observation that these men are least likely to demonstrate
adverse pathology, extraprostatic disease, or biochemical re-
lapse after radical therapy and are, therefore, most represen-
tative of the ‘‘overtreated’’ prostate cancer population.13,14
It would be correct to point out that this opinion was pre-
dominantly nested in members from the United States or
Canada and represented the position of the SUO. The diver-
gent view was that men with intermediate grade, Gleason
score 7, should also be included—this opinion meant that
focal therapy could also be an alternative low-morbidity
therapy for those men who did require treatment because of
the presence of Gleason pattern 4 disease. This viewpoint
recognized that a number of series and clinical trials had al-
ready recruited and treated men with nondominant Gleason
pattern 4, both in Europe and North America. A consensus
recommendation was reached on this point, with the panel
agreeing that low-volume, nondominant Gleason pattern 4
found on template transperineal biopsies would probably not
represent a high-risk strategy for focal therapy and should be
permissible. Any Gleason pattern 4 found on standard
transrectal biopsies, however, should be regarded with cau-
tion, although the panel accepted that a strict recommenda-
tion to exclude this would not be consistent with many
current focal therapy protocols.
Assessment of patients who may be candidates
for focal therapy
It was agreed that current transrectal ultrasonography
(TRUS) biopsy regimens are inadequate for the purposes of
candidate selection for focal therapy. The reason for this is
that the random and systematic error associated with TRUS-
guided biopsy was overcome, in the past, by treating the
whole prostate with either surgery or with radiation. It was
agreed that in using a whole-gland approach, the character-
ization of the cancer was less important than it is for the
therapies of active surveillance and focal therapy. Active
surveillance imposes the additional burden of accurate risk
stratification, because few clinicians would advise this form of
treatment to men with moderate- or high-risk disease. The
process of repeated biopsy addresses this to some degree.15
Many agree that TRUS biopsy is still too inaccurate for this
purpose, however. To this burden of accurate risk stratifica-
tion, the clinician who is advising the patient of his suitability
for focal therapy has the additional task of defining the to-
pography of the disease—in other words, its location and
extent.16 In a sense, the focal therapist is more concerned with
the limits of where disease is absent to a high level of certainty.
TRUS-guided biopsy serves this interest poorly.17
There existed unanimous agreement that the current gold
standard for characterizing men who are considering focal
therapy is transperineal prostate biopsy using a template-
guided approach.18,19 When used with a 5-mm sampling
frame, this approach can rule in and rule out prostate cancer
foci of 0.5 cc and 0.2 cc volume with 90% certainty.20
It was accepted that this approach is not yet widely avail-
able and carried a high burden on healthcare services because
Table 2. Items Selected for Discussion
Item 1. Definitions of focal therapy
Item 2. Patient selection of focal therapy
Item 3. Diagnostic pathway
Item 4. Treatment modalities capable of focal therapy
Item 5. Evaluation of outcome and follow-up
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of its requirement for anesthesia, pathology processing, and
reporting time.
The contributors to the consensus panel were convinced
that imaging was going to play an important role in selecting
patients as suitable candidates in the future.21 The contribu-
tors were less convinced of the current role of imaging in the
diagnostic pathway for these men.22 There was overall
agreement that multiparametric functional MRI and new
TRUS techniques show promising results in multiple centers
and publications in relation to characterizing men with
prostate cancer and localizing their tumor. Based on these
results, it is expected that these techniques will play a major
role in the future for the selection, performance, and follow-up
of patients with focal therapy. Therefore, multicenter studies
need to be urgently prioritized.23–25
Treatment modalities for focal therapy
The consensus panel was in agreement that traditional
therapies did not have the attributes to treat in a focal manner.
Surgery and external beam radiation therapy were not yet
ready for use in focal treatment. Most focal therapies to date
have been achieved with ablative technologies: Cryotherapy,
high intensity focused ultrasound (HIFU), or photodynamic
therapy. At present, focal therapy using cryosurgery has the
most experience.26 The published data relating to these tech-
nologies are presented and discussed in recent reviews and a
number of prospective single-center trials are under way.27
Most recently, the first report of the use of thermal laser for
focal therapy has been published.28
The role of radiotherapeutic approaches is at present less
clear. Possible options, however, include high-dose-rate bra-
chytherapy, low-dose-rate seed implantation brachytherapy,
intensity modulated, hypofractionated photon irradiation,
and proton beam therapy. It was agreed by the group, how-
ever, that none of these had been tried in the primary focal
therapy arena. Experimental technologies, such as micro-
wave, electroporation, and radiofrequency interstitial tumor
ablation and magnetic nanoparticle thermotherapy are also
currently under investigation in early clinical trials. All of the
above have the attributes that can, at least from a technical
perspective, treat a specific area or one lobe of the prostate
with little if any effect on the contralateral lobe.
Evaluation of outcome and follow-up
There are three main aspects to evaluating the outcome of
focal therapy: The assessment of functional status, the onco-
logic efficacy, and the impact on subsequent therapy.
The first key outcome domain is functional status that, in
turn, relates to disease-specific and generic QoL.29 The panel
agreed that case series had demonstrated that focal therapy
could achieve significantly lower toxicity rates with preser-
vation of genitourinary function approaching 80% to 90%
after focal cryosurgery or HIFU.30 All but a few of these out-
comes, however, were patient reported on validated ques-
tionnaires. There are no validated instruments that have been
designed for use in men who are undergoing focal therapy. As
a result, the consensus panel has recommended that existing
self-reported measures of health status should be used in
order to compare outcome to other treatment modalities. The
scales in current use that would assess the components of
functional status include the following: International Prostate
Symptom Score, IIEF, International Continence Society scale
of urinary continence, Functional Assessment of Cancer
Therapy-Prostate, EuroQoL, Short Form-36, and EORTC
QoL.
The panel was in agreement that determining oncologic
efficacy at this stage of the evolution of the technology was
best achieved by an interval post-treatment biopsy of the
treated part of the prostate. Given that the panel re-
commended that patients are initially characterized by
transperineal template-guided biopsies, it seemed to the panel
sensible that the same test is used to assess absence of cancer.
The panel does accept, however, that this will pose a signifi-
cant burden on both the patient and the healthcare system,
and thus, at this time, a TRUS-based office biopsy may be a
reasonable alternative. It was the view of the panel that post-
treatment evaluation by biopsy should take place between
6 and 12 months after treatment because such a time interval
Table 3. Candidate Selection for Focal Therapy
1. Candidates for focal therapy should ideally undergo transperineal template mapping biopsies, although
a state-of-the-art multifunctional MRI with TRUS biopsy at expert centers may be acceptable.
2. Candidates for focal therapy should have a life expectancy of 10 or more years.
3. Patients with previous prostate surgery should be counseled with caution.
4. Patients with previous radiotherapy to the prostate or pelvis should not be treated until more data are available,
although the panel accepted that focal salvage therapy may be a possibility in the future.
5. The effects of focal therapy on men with lower urinary tract symptoms are not well known. These men should be
counseled with caution.
6. There will be specific attributes that are more related to the energy source than to focal therapy in general. Issues such
as prostate size, presence of prostatic calcification, cysts, TUR cavity, access to rectum, and concurrent inflammation
of rectal mucosa may need to be taken into consideration when selecting the optimal therapy.
7. Focal therapy should be limited to patients of low to moderate risk
8. Focal therapy should be limited to men with clinical T2a or less N0M0 disease
9. Focal therapy should be limited to men with radiologicT2b N0M0 disease
10. Defining the topography of the cancer is important. Disease that is predominantly apical or anterior in disposition may
be technically difficult to manage with existing treatment modalities.
11. The long-term effects of focal therapy on potency=erectile functions are not known. Men should be counseled in this
regard before therapy
MRI¼magnetic resonance imaging; TRUS¼ transrectal ultrasonography; TUR¼ transurethral resection.
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would allow for resolution of inflammatory changes and es-
tablishment of stable scar tissue.
In the future, it may be that imaging, particularly with
multi-functional MRI, or contrast-enhanced ultrasonography
may be useful in reducing the burden of post-treatment bi-
opsies, although this needs further evaluation before any
recommendation is made.19,28,31,32
Biomarkers in the interval between biopsy evaluations will
play an important role, although the panels’ view was that the
prostate-specific antigen (PSA) kinetics of partially treated
prostate tissue are largely unknown. The panel felt that PSA
should be measured at least as much as is common practice for
standard therapy. As such, the panel recommended PSA
measurements at 3-monthly intervals for the first year after
treatment and every 6 months thereafter. Long-term follow-
up, including biomarkers, biopsies, and imaging, is important
to understand the effect on the treated side and the natural
history of the untreated tissue.
The role of other biomarkers, such as PCA3, is at present
not well defined. They may prove to be useful in monitoring
the nontreated region. The panel strongly recommended the
collection of urine, serum, and tissue for archiving so that
future interrogation of such archives can be used to develop
biomarkers that can be linked to long-term outcomes after
focal therapy.
The third key outcome domain relates to the impact of focal
therapy on subsequent treatments. The panel acknowledged
that primary treatment fails in a number of men irrespective
of the kind of treatment they were allocated. The effect of focal
therapy on the likely salvage procedures of surgery and ra-
diotherapy remains unknown. The panel was unanimous that
this aspect of focal therapy be monitored closely so that
men are not placed at undue risk if their primary therapy was
to fail.
Conclusion
The consensus process derived considerable agreement in
all items tabled. Where no agreement was possible, the in-
evitable resolution was the recommendation of further re-
search, because in nearly all instances, disagreement was
because of clinical uncertainty and not divergent clinical
opinion.
While most of the recommendations that resulted remain
uncontroversial, the reader should interpret our results in
light of certain methodologic limitations. The first of these
relates to the composition of the group. The participants were
selected for their expertise in focal therapy and were therefore
by default enthusiasts. There are plenty of skeptics who, had
they been present, would have voted in different ways. As a
result, the recommendations may not be representative of the
opinion of the wider urologic community and may therefore
be difficult to generalize beyond those interested in under-
taking or evaluating this novel approach.
The second reasonable criticism may lie with our approach.
We chose, for reasons of convenience, an informal consensus
process in which no quantitative measure of agreement was
derived. Participants, at the time of deriving consensus, were
required to vote for or against. If the vote was close to or
unanimous, the vote was carried. If the vote was split, it was
deemed that agreement was not possible. The bias that can
result from such an approach is that vociferous and forceful
personalities can exert too much influence in the overall
scoring. While we accept this criticism, this effect was miti-
gated by the presence of two chairpersons and introduction of
topics by different invited experts. Before closure of any topic,
views were invited from all those present.
Despite these methodologic limitations, we believe that the
consensus process was helpful in refining some of the con-
ceptual and practical considerations that relate to focal ther-
apy for men with localized prostate cancer. The participation
in this meeting and endorsement of the consensus report by
representatives from the ESTRO, EORTC, and the EAU
guidelines committee on prostate cancer, as well as ESUT,
SUO, and the Endourological Society signify its position and
carries additional weight to the outcomes. Obviously, this is a
field that will progress rapidly. Future meetings such as this
will have the benefit of including data that are derived from
phase II clinical trials on which further recommendations can
be made.
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